## (19) World Intellectual Property Organization

International Bureau



## 

(43) International Publication Date 27 May 2004 (27.05.2004)

PCT

(10) International Publication Number WO 2004/044176 A3

C12N 15/64. (51) International Patent Classification7: A61K 31/70

(21) International Application Number:

PCT/US2003/036237

(22) International Filing Date:

12 November 2003 (12.11.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/425,286

12 November 2002 (12.11.2002) US

(71) Applicants and

- (72) Inventors: DEISSEROTH, Albert, B. [US/US]; 9610 Limar Way, San Diego, CA 92129 (US). CHANG, Yucheng [CN/US]; 5150 Balboa Arms Drive, #A3, San Diego, CA 92121 (US). ZHANG, Lixin [CN/US]; 470 Prospect Street, #65, New Haven, CT 06511 (US).
- (74) Agents: WARBURG, Richard, J. et al.; Foley & Lardner, P.O. Box 80278, San Diego, CA 92138-0278 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 26 August 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ADENOVIRAL VECTOR VACCINE

(57) Abstract: Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/36237

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12N 15/64; A61K 31/70					
US CL: 435/91.4; 514/44  According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/91.4; 514/44					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched .					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS Online, MEDLINE, EAST, DERWENT					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages			Relevant to claim No.	
Т	ZHANG, L. et al. An adenoviral vector cancer vaccine that delivers a tumor-asociated antigen/CD40 ligand fusion protein to dendritic cells. PNAS. 09 December 2003, Vol. 100, No. 25, pages 15101-15106, see entire document.				
A	LIU, Y. et al. Adenovirus mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8+ cytotoxic T-cell activation and anti-tumor immunity. Cancer Gene Therapy. 2002, Vol. 9, pages 202-208. see entire document.			1-34	
	·				
			1		
Further documents are listed in the continuation of Box C. See patent family annex.					
Special categories of clted documents:  "A" document defining the general state of the art which is not considered to be			date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
of particular relevance  "E" earlier application or patent published on or after the international filing date					
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"Y"	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is		
"O" document referring to an oral disclosure, use, exhibition or other means			combined with one or more other such being obvious to a person skilled in the	documents, such combination e art	
"P" document published prior to the international filing date but later than the priority date claimed			"&" document member of the same patent family		
			Date of mailing of the international search report		
10 May 2004 (10.05.2004)  Name and mailing address of the ISA/US  Authorized officer					
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450			J. Eric Angell Saulrence for		
Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Telephone	No. (703) 308-0196		

Form PCT/ISA/210 (second sheet) (July 1998)